Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool May 26, 2009 Dave Mock	A Big Upgrade for Spartan Motors This bullish call on automotive parts manufacturer Spartan Motors comes from more than just one Motley Fool analyst.
The Motley Fool February 15, 2008 Rich Smith	Under the Hood at Spartan Motors Fiscal 2007's results were mixed. Revenue exploded upward, but many factors combine to decrease profit margins.
The Motley Fool July 21, 2011	Spartan Motors Earnings Preview Spartan Motors, international engineer and manufacturer of custom motor vehicle chassis and bodies, will unveil its latest earnings on Tuesday.
The Motley Fool January 15, 2008 Rich Smith	Spartan's Luxurious Spending A smaller player in the defence industry, Spartan Motors, announces its repurchase of 250,000 shares.
National Defense October 2006 Sandra I. Erwin	Vehicle Maker Wins Iraqi Army Deal, Rushes To Expand Production A recent Defense Department contract to acquire more than 1,000 "mine-protected" armored vehicles for the Iraqi Army has prompted Force Protection Inc. to both expand its internal production capacity and seek outside help.
The Motley Fool February 12, 2008 Rich Smith	Foolish Forecast: Under the Hood at Spartan Motors In advance of earnings, analysts expect truck chassis specialist Spartan Motors to post a huge quarterly sales jump.
The Motley Fool February 13, 2007 Brian Lawler	Rock-Solid News From Onyx Results show that the drug Nexavar works in another type of cancer. But investors need to consider other issues when taking a closer look at this pharma.
The Motley Fool May 18, 2007 Rich Smith	Force Protection: Strong, Silent, Superb Investors, this military manufacturer's few words are all good ones.
The Motley Fool January 31, 2007 Matt Koppenheffer	The 5-Sigma Report A look at the stocks that experienced serious volatility last week. 21st Century Insurance Group... LECG... Novelis... National Interstate Group... Technitrol...
The Motley Fool December 7, 2010 Jim Mueller	Rising Star Buy: Oshkosh A defense contractor, but so much more. There's the opportunity.
National Defense February 2007 Sandra I. Erwin	Military Services in the Market for 4,000 Blast-Proof Vehicles Expectations that U.S. troops will not leave Iraq for the foreseeable future have prompted the military services to request an additional 4,000 mine-resistant armored vehicles.
The Motley Fool August 27, 2007 Brian Orelli	Onyx: Old News Is Good News Onyx set a 52-week high today, even though the good news wasn't all that new. After the recent dearth of FDA approvals, investors may be flocking to a drug that's nearly certain to get the agency's thumbs-up.
The Motley Fool June 13, 2007 Brian Orelli	Evaluating a One-Trick Pony There is no doubt that investors should have bought Onyx Pharmaceuticals at its lows last December: The stock has tripled since then. The more important question is, what should you do now? Let's take a look at where Onyx is going.
The Motley Fool October 8, 2010 Luke Timmerman	Onyx Delays Cancer Drug Application As FDA Asks for More Data Shares fell about 7% in after-hours trading Thursday evening.
The Motley Fool September 23, 2009 Brian Orelli	Nexavar, and Onyx, Nail It Investors have been anxiously awaiting this release of data from Onyx Pharmaceuticals' phase 2 trial testing Nexavar against breast cancer.
The Motley Fool December 5, 2006 Brian Lawler	Slight Setback for Onyx Onyx shares fell on disappointing news, but there are other opportunities for the one-drug wonder.
The Motley Fool March 22, 2005 Charly Travers	Do Good Drugs Guarantee Investment Success? By the time you know a drug is good, are you late to the party? Instead of trying to catch a train that has already zipped by, try investing in drug programs well in advance of phase 3 trials.
The Motley Fool February 21, 2008 Brian Orelli	Onyx's Double Dose of Trouble Poor clinical trial data and a lack of profits hit the drugmaker hard. Investors, take note.
The Motley Fool July 24, 2011	Spartan Stores Earnings Preview Spartan Stores will unveil its latest earnings on Wednesday, July 27.
The Motley Fool April 28, 2009 Brian Orelli	Headline? Bad! Unexpected? No! For a company that only has one drug on the market, stopping a failing phase 3 clinical trial that's designed to expand the market of that drug is usually a major blow. But Onyx Pharmaceuticals was able to shrug it off.
Military & Aerospace Electronics October 2008 Courtney E. Howard	Force Protection Rolls Out First Ridgback Vehicles for British Ministry of Defence Representatives of Force Protection Industries, together with officials from the U.S. government and the British Ministry of Defence (MOD), rolled out the first five Ridgback armored combat vehicles.
The Motley Fool May 7, 2008 Brian Orelli	Black Onyx, but Not for Long Onyx posts a stellar quarter, but earnings for the pharmaceuticals company are headed in the other direction for the rest of the year.
The Motley Fool August 8, 2007 Brian Orelli	Onyx Is Almost There Onyx Pharmaceutical narrowed losses for the quarter, and things should improve even more in the months to come, even as their bottom line is still being hampered by endless clinical trials.
The Motley Fool November 8, 2007 Brian Orelli	Investors Prefer Black Onyx Sales of Onyx's only drug, Nexavar, exceeded $100 million in the third quarter, enough for Onyx to show a profit. Investors, take note.
The Motley Fool August 6, 2008 Brian Orelli	Onyx in the Black -- for Now Positive earnings, but losses may be ahead. Will Onyx be able to keep costs under control?
The Motley Fool August 5, 2009 Brian Orelli	Potential Can't Buy Me Love It's sad when investors can't get excited about a company doubling its earnings per share and posting 19% growth in sales of its drug, but Onyx isn't going to get any love until it gets some positive clinical trial data.
The Motley Fool October 1, 2009 Brian Orelli	Geez, Lighten Up, Mr. Market! Investors dish out undue punishment to Onyx's stock.
The Motley Fool May 14, 2007 Brian Lawler	Onyx Rocks The oncology-focused biotech announces first-quarter financial results. Investors, take note.
The Motley Fool June 28, 2007 Brian Orelli	Onyx's Hard at Work Onyx's future depends on getting Nexevar approved for new indications. The liver cancer expansion is a nice start, and it should bring Onyx into the black. Investors, take note.
Military & Aerospace Electronics December 2009	Infrared Sensor for Armored Vehicle Night Vision is Aim of BAE Contract BAE Systems will produce a system of infrared sensors and related vetronics that provide 24-hour, all-weather visibility to operators of U.S. Army and Marine Corps armored vehicles.
The Motley Fool February 1, 2008 Rich Duprey	What Is the Fate of American LaFrance? Computer problems lead the fire engine maker to file for bankruptcy protection.
The Motley Fool June 21, 2007 Brian Lawler	Onyx on the Clock The one-drug wonder's partner files a marketing application to expand the use of its lead drug. Investors, take note.
The Motley Fool February 24, 2010 Brian Orelli	A Profitable One-Drug Wonder! It's kind of impressive that Onyx Pharmaceuticals has made a profit two years in a row: $0.03 per share in 2008, and a much healthier $0.27 per share last year.
National Defense February 2012 Stew Magnuson	Tough War Lessons Force Military Vehicle Programs To Consider Fuel Efficiency Moving fuel to and around battle zones that have no "front lines" has an extraordinarily high price in terms of money and lives.
The Motley Fool October 12, 2009 Brian Orelli	Onyx Strikes Gold A nice pipeline pickup for this pharmaceutical company.
National Defense February 2011 Jean & Magnuson	Industry Execs Ponder a Shrinking Tactical Wheeled Vehicle Market Military truck manufacturers are beginning to worry about the long-term future of the industry.
The Motley Fool May 8, 2009 Brian Orelli	Growth in All the Wrong Places The potential of Onyx's tumor drug Nexavar will always be a major component in the company's value, but investors should watch the growth in current indications -- and where it's coming from -- in case the additional indications don't pan out.
The Motley Fool February 24, 2009 Brian Orelli	Back to the Red, but Not for Long After a few quarters in the black, Onyx Pharmaceuticals slips back into the red, reporting a loss of $30 million for the fourth quarter.
National Defense February 2010 Erwin, Magnuson & Jean	Army, Marines Mull Over Options to Modernize Truck Fleets The Defense Department has been on a truck-buying spree for the past several years, and the demand will remain high for some time. But truck manufacturers don't expect the good times to last too much longer
The Motley Fool September 25, 2007 Brian Orelli	Onyx Moves Ahead Bayer and Onyx score a positive recommendation from an EU committee, moving one step closer to being able to market their cancer-fighting drug Nexavar in Europe.
National Defense August 2011 Stew Magnuson	Army, Car Makers Push Ahead With Driverless Vehicle Research When it comes to concepts for vehicles that can drive themselves on highways or city streets, the military and automakers have been working on similar paths for several years.
National Defense June 2012 Stew Magnuson	Visionaries Foresee Radically Different Military Vehicles The Defense Advanced Research Projects Agency's Adaptive Vehicle Make program seeks to reinvent the way vehicles are designed and built. It is looking to revamp and speed up the entire acquisition process, from the drawing board to the assembly line.
Military & Aerospace Electronics April 2008	BAE Systems to Provide Transparent Armored Gun Shield for the U.S. Marine Corps BAE Systems to deliver 360 Marine Corps Transparent Armored Gun Shield (MCTAGS) turret kits for use on HMMWV vehicles and Mine Resistant Ambush Protected vehicles, better-known as MRAPs.
The Motley Fool June 5, 2007 Billy Fisher	Onyx on Fire It is readily apparent that investors in the biopharma will sink or swim on the future results of Nexavar. The ASCO meeting marks an integral win for the company, but only time will tell whether the drug can push the company into the black.
The Motley Fool November 20, 2007 Brian Orelli	Explaining Onyx Pharmaceuticals' Sell-Off The FDA approved Nexavar as a treatment for liver cancer, but the good news causes a sell-off of the stock.
The Motley Fool June 2, 2009	2 Stocks Hitting High Notes These stocks are bucking the trend and hitting new highs. Take a look at: Spartan Motors, Inc. ... Randgold Resources Ltd. ...
The Motley Fool July 26, 2010 Brian Orelli	Up 20%! Guess That Hedge Wasn't Needed Onyx reports positive data for its recently acquired multiple myeloma drug.
The Motley Fool November 7, 2008 Brian Orelli	Onyx -- Still Waiting Onyx licenses a pre-clinical drug from England's BTG International -- but it's got a new problem to worry about.
The Motley Fool April 8, 2008 Brian Orelli	Songs of the One-Drug Wonders Will these companies become big-name drugmakers or get lost in history? Let's take a quick look at: Abraxis Bioscience... Elan... Amylin Pharmaceuticals... Onyx Pharmaceuticals...